Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Author
Hochmair, M. J.
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Ji, J. H.
ÖZGÜROĞLU, MUSTAFA
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.